AIM Specialty Health® medical oncology director receives dual honors for significant contributions to cancer care
Dr. Michael Fisch honored as American Society of Clinical Oncology Fellow, CMS panelist
Chicago, IL, – June 1, 2017 – Michael Fisch, MD, MPH, FACP, FAAHPM, medical director of medical oncology for AIM Specialty Health®, has been named a fellow for the American Society of Clinical Oncology. The recipients of this honor, considered ASCO's most prestigious award, include researchers, patient advocates, and global oncology leaders who have worked to transform cancer care around the world. Fisch and the honorees and will be recognized during the ASCO Annual Meeting in June in Chicago.
Fisch was also among a panel of experts featured at the Centers for Medicare & Medicaid Services March 2017 meeting in Baltimore. Members of the panel, known as Medicare Evidence Development and Coverage Advisory Committee, discussed the best health outcomes to include in studies for heart failure treatment technologies.
"These honors speak volumes about Mike's leadership in helping AIM make a significant contribution in oncology care with our evidence-based approach to developing clinical guidelines and pathways, as well as our value-based reimbursement programs that improve quality and lower costs,"
"These honors speak volumes about Mike's leadership in helping AIM make a significant contribution in oncology care with our evidence-based approach to developing clinical guidelines and pathways, as well as our value-based reimbursement programs that improve quality and lower costs," said Brandon Cady, president and chief executive officer.
Julie M. Vose, MD, MBA, FASCO, immediate past president of ASCO and chair of the Special Awards committee, said this about Dr. Fisch and the other recipients: "The meaningful contributions from each of this year's honorees are leading to improvements throughout the cancer care continuum. These oncology leaders are changing the lives of people with, or at risk for, cancer, and ASCO is proud to honor them with our most prestigious awards."
The FASCO distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Their efforts benefit ASCO, the specialty of oncology, and, most importantly, the patients for whom they serve. With more than 30,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. Its single purpose: to improve the care of people with cancer.
The Medicare Evidence Development & Coverage Advisory Committee provides independent guidance and expert advice to CMS on specific clinical topics. The panelist honor is prestigious as only up to 100 experts in clinical and administrative medicine, biologic and physical sciences, public health administration, patient advocacy, health care data and information management and analysis, health care economics, and medical ethics are invited to serve on the MEDCAC. No more than 15 members with knowledge specific to the topic in question are invited to serve on the panel for each MEDCAC meeting.
Prior to joining AIM, Fisch, served as faculty at MD Anderson Cancer Center in Houston, initially in the Department of Palliative Care and Rehabilitation. He then led the MD Anderson Community Clinical Oncology Program Research Base. He subsequently served for five years as the founding chair of the Department of General Oncology. In his role, Fisch led a group of clinical faculty who managed a broad mix of cancer patients in a variety of community and academic settings and those involved in clinical and basic research.
In his role at AIM, Fisch works closely with the company's payer clients and their provider partners to deliver clinical expertise for the ongoing expansion of the AIM Oncology Solution platform. It serves more than 18 million health plan members across the country.
AIM Specialty Health® provides clinical solutions that drive appropriate, safe and affordable care. Serving more than 50 million members across 50 states, D.C. and US territories, AIM promotes quality care through use of evidence-based medicine guidelines, provides consumer value and delivers significant cost of care savings in radiology, cardiology, oncology, specialty drugs, sleep medicine, musculoskeletal and pain management, and genetic testing. As a national leader in specialty benefits management, AIM positions health plans, providers and employers to deliver on the promise of quality improvement in health care through an integrated suite of solutions combining clinical excellence, technology and superior customer service. AIM is a wholly owned subsidiary of Anthem, Inc. (ANTM). For more information, visit www.aimspecialtyhealth.com.